EP1165137B1 - Preparation contenant de la sphingomyeline pour l'amelioration du traitement des tumeurs - Google Patents

Preparation contenant de la sphingomyeline pour l'amelioration du traitement des tumeurs Download PDF

Info

Publication number
EP1165137B1
EP1165137B1 EP00916269A EP00916269A EP1165137B1 EP 1165137 B1 EP1165137 B1 EP 1165137B1 EP 00916269 A EP00916269 A EP 00916269A EP 00916269 A EP00916269 A EP 00916269A EP 1165137 B1 EP1165137 B1 EP 1165137B1
Authority
EP
European Patent Office
Prior art keywords
sphingomyelin
tumor
therapy
administered
see
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP00916269A
Other languages
German (de)
English (en)
Other versions
EP1165137A1 (fr
Inventor
David Modrak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Center for Molecular Medicine and Immunology
Original Assignee
Center for Molecular Medicine and Immunology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Center for Molecular Medicine and Immunology filed Critical Center for Molecular Medicine and Immunology
Priority to EP06075201A priority Critical patent/EP1666045B1/fr
Publication of EP1165137A1 publication Critical patent/EP1165137A1/fr
Application granted granted Critical
Publication of EP1165137B1 publication Critical patent/EP1165137B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Claims (7)

  1. Utilisation d'une quantité thérapeutiquement efficace de sphingomyéline dans la préparation d'un médicament destiné à accroître une thérapie cytotoxique antitumorale utilisant la chimiothérapie, dans laquelle ladite sphingomyéline est administrée au patient conjointement avec une anthracycline.
  2. Utilisation suivant la revendication 1, dans laquelle l'anthracycline est la doxorubicine.
  3. Utilisation suivant l'une quelconque des revendications précédentes, dans laquelle la composition de sphingomyéline est coadministrée avec la thérapie cytotoxique antitumorale.
  4. Utilisation suivant la revendication 1, dans laquelle ladite sphingomyéline est administrée avant l'administration de la thérapie antitumorale.
  5. Utilisation suivant l'une quelconque des revendications précédentes, dans laquelle le patient est un patient humain.
  6. Utilisation suivant l'une quelconque des revendications précédentes, dans laquelle la doxorubicine est acheminée à une cible consistant en cellules tumorales en utilisant un anticorps ou un fragment d'anticorps.
  7. Utilisation suivant la revendication 6, dans laquelle ladite thérapie est acheminée à une cible consistant en cellules tumorales en utilisant un anticorps ou un fragment d'anticorps qui est un anticorps monoclonal ou un fragment d'anticorps monoclonal.
EP00916269A 1999-03-25 2000-03-24 Preparation contenant de la sphingomyeline pour l'amelioration du traitement des tumeurs Expired - Lifetime EP1165137B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06075201A EP1666045B1 (fr) 1999-03-25 2000-03-24 Préparation contenant de la sphingomyéline pour le traitement de la polyarthrite rhumatoide

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12618999P 1999-03-25 1999-03-25
US126189P 1999-03-25
PCT/US2000/006431 WO2000057916A1 (fr) 1999-03-25 2000-03-24 Preparation contenant de la sphingomyeline pour l'amelioration du traitement des tumeurs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP06075201A Division EP1666045B1 (fr) 1999-03-25 2000-03-24 Préparation contenant de la sphingomyéline pour le traitement de la polyarthrite rhumatoide

Publications (2)

Publication Number Publication Date
EP1165137A1 EP1165137A1 (fr) 2002-01-02
EP1165137B1 true EP1165137B1 (fr) 2006-08-02

Family

ID=22423475

Family Applications (2)

Application Number Title Priority Date Filing Date
EP00916269A Expired - Lifetime EP1165137B1 (fr) 1999-03-25 2000-03-24 Preparation contenant de la sphingomyeline pour l'amelioration du traitement des tumeurs
EP06075201A Expired - Lifetime EP1666045B1 (fr) 1999-03-25 2000-03-24 Préparation contenant de la sphingomyéline pour le traitement de la polyarthrite rhumatoide

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP06075201A Expired - Lifetime EP1666045B1 (fr) 1999-03-25 2000-03-24 Préparation contenant de la sphingomyéline pour le traitement de la polyarthrite rhumatoide

Country Status (9)

Country Link
US (2) US6541462B1 (fr)
EP (2) EP1165137B1 (fr)
JP (1) JP2002540172A (fr)
AT (2) ATE512664T1 (fr)
AU (1) AU3740000A (fr)
CA (2) CA2707691C (fr)
DE (1) DE60029762T2 (fr)
ES (1) ES2269121T3 (fr)
WO (1) WO2000057916A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7683044B2 (en) * 1999-03-25 2010-03-23 Center For Molecular Medicine And Immunology Sphingomyelin therapy of autoimmune disease
ATE512664T1 (de) * 1999-03-25 2011-07-15 Ct For Molecular Medicine And Immunology Sphingomyelin enthaltende zusammensetzung zur behandlung der rheumatoiden arthritis
WO2007034927A1 (fr) * 2005-09-22 2007-03-29 Snow Brand Milk Products Co., Ltd. Médicaments, aliments et boissons ou aliments pour animaux contenant de la sphingomyéline
US9056129B2 (en) * 2007-02-09 2015-06-16 Northeastern University Precision-guided nanoparticle systems for drug delivery
WO2014116866A1 (fr) 2013-01-24 2014-07-31 Memorial Sloan Kettering Cancer Center Procédé pour diagnostiquer ou traiter des tumeurs au moyen de liposomes contenant de la sphingomyéline
US9851358B2 (en) * 2014-01-08 2017-12-26 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for preventing or reducing metastatic dissemination
GB201414464D0 (en) * 2014-08-14 2014-10-01 Technion Res & Dev Foundation Compositions and methods for therapeutics prescreening

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5859912A (ja) * 1981-10-06 1983-04-09 Green Cross Corp:The 鎮痛消炎物質脂肪乳剤
DE69518627T2 (de) 1994-02-02 2001-01-11 Liposome Co Inc Pharmazeutisch wirksame verbindungen und liposome und verfahren zu deren herstellung
US5543152A (en) * 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5800833A (en) * 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
ATE279185T1 (de) * 1995-12-28 2004-10-15 Mitsubishi Pharma Corp 2-amino-2-(2-(4-octylphenyl)ethyl)propan-1,3-di l enthaltendes arzneimittel zur topischen anwendung zur behandlung von erkrankungen die durch eine störung des immunsystems hervorgerufen werden
CA2286177C (fr) * 1997-04-07 2011-06-21 Daiichi Pharmaceutical Co., Ltd. Composition pour le transfert de genes dans des cellules
ATE512664T1 (de) * 1999-03-25 2011-07-15 Ct For Molecular Medicine And Immunology Sphingomyelin enthaltende zusammensetzung zur behandlung der rheumatoiden arthritis

Also Published As

Publication number Publication date
WO2000057916A1 (fr) 2000-10-05
ATE512664T1 (de) 2011-07-15
ATE334686T1 (de) 2006-08-15
US20030228257A1 (en) 2003-12-11
US6541462B1 (en) 2003-04-01
US7288534B2 (en) 2007-10-30
EP1666045B1 (fr) 2011-06-15
EP1165137A1 (fr) 2002-01-02
EP1666045A1 (fr) 2006-06-07
CA2707691A1 (fr) 2000-10-05
AU3740000A (en) 2000-10-16
DE60029762D1 (de) 2006-09-14
CA2368676C (fr) 2010-09-07
CA2368676A1 (fr) 2000-10-05
CA2707691C (fr) 2013-09-03
JP2002540172A (ja) 2002-11-26
ES2269121T3 (es) 2007-04-01
DE60029762T2 (de) 2007-10-18

Similar Documents

Publication Publication Date Title
Russo et al. The novel butyrate derivative phenylalanine‐butyramide protects from doxorubicin‐induced cardiotoxicity
Evison et al. Mitoxantrone, more than just another topoisomerase II poison
JP2019065047A (ja) ｍＲＮＡのＣＮＳ送達及びその使用方法
US20060009413A1 (en) Methods and compositions for protecting or treating muscarinic receptors through administration of pyrophosphate analog in subjects exposed to toxic or carcinogenic metals or metal ions
WO2003105862A1 (fr) Strategies d'appauvrissement d'energie in vivo permettant de tuer des cellules cancereuses resistant aux medicaments
WO1996025947A2 (fr) Induction de selectine e pour agents de ciblage therapeutiques
JP2002524473A (ja) プラスミドベクターのメチル化
EP1165137B1 (fr) Preparation contenant de la sphingomyeline pour l'amelioration du traitement des tumeurs
Arcamone et al. Configurational requirements of the sugar moiety for the pharmacological activity of anthracycline disaccharides
Milane et al. Mitochondrial nanomedicine: Subcellular organelle-specific delivery of molecular medicines
JP2009531301A (ja) 癌治療のためのヘキソース化合物
Wang et al. Effective conversion of irinotecan to SN-38 after intratumoral drug delivery to an intracranial murine glioma model in vivo
Horsman et al. Tumor radiosensitizers—current status of development of various approaches: report of an International Atomic Energy Agency meeting
Li et al. Risks and rewards of targeting NAD+ homeostasis in the brain
NZ517634A (en) Compositions and methods for L-nucleosides, L-nucleotides, and their analogs
AU2004242498B2 (en) Sphingomyelin containing preparation for the enhancement of tumor therapy
US8778337B2 (en) Use of S-adenosylmethionine (SAM) and superoxide dismutase (SOD) for the preparation of medicaments for the treatment of alzheimer's disease
JP2007517004A (ja) Ｖａｐ−１／ｓｓａｏ阻害剤としての使用のためのアミノグリコシド系抗生物質
KR101746901B1 (ko) 강글리오사이드를 포함하는 병용 항암 치료제
Asatryan Age-dependence of Poly (Adenosine Diphosphate-Ribos) yl Polymerase 1 Inhibition in Liver and Thymocyte Nuclei after the Treatment of Rats with Cisplatin
Johnston et al. Cellular Pharmacology of 3′-(3-Cyano-4-morpholinyl)-3′-deaminoadriamycin and Structural Analogues in Human Colon Carcinoma HT-29 Cells in Vitro
Poison the saturated derivative of lipstatin Menu
Mahapatra et al. A Review on:“Recent Updates on Poly-Adp-Ribosylation (Parylation) in Physiology and Pathology”
JP2006206607A (ja) 癌細胞内ヌクレアーゼ活性化剤

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011025

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20020213

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/688 20060101AFI20060213BHEP

Ipc: A61K 31/704 20060101ALI20060213BHEP

Ipc: A61P 35/00 20060101ALI20060213BHEP

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20060802

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060802

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060802

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060802

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060802

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060802

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60029762

Country of ref document: DE

Date of ref document: 20060914

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061102

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061102

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070102

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

ET Fr: translation filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2269121

Country of ref document: ES

Kind code of ref document: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20070503

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070331

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070326

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061103

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20070326

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070326

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060802

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070324

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20120330

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20130321

Year of fee payment: 14

Ref country code: FR

Payment date: 20130408

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20130320

Year of fee payment: 14

REG Reference to a national code

Ref country code: NL

Ref legal event code: V1

Effective date: 20141001

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20140324

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20141128

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140331

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140324

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20141001

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140324

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20160330

Year of fee payment: 17

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60029762

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171003